CeriBell (NASDAQ:CBLL) Announces Earnings Results, Misses Estimates By $0.04 EPS

CeriBell (NASDAQ:CBLL) posted its earnings results on Tuesday. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04), FiscalAI reports. The company had revenue of $29.34 million during the quarter, compared to analysts’ expectations of $29.16 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.

CeriBell Stock Performance

Shares of CBLL stock traded up $1.31 on Tuesday, hitting $28.27. The company had a trading volume of 664,051 shares, compared to its average volume of 366,242. CeriBell has a twelve month low of $10.85 and a twelve month high of $28.89. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16. The firm has a market cap of $1.09 billion, a P/E ratio of -16.06 and a beta of 0.94. The company has a 50-day moving average price of $24.98 and a 200-day moving average price of $20.82.

Insider Activity at CeriBell

In related news, CEO Xingjuan Chao sold 20,846 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $25.03, for a total transaction of $521,775.38. Following the transaction, the chief executive officer directly owned 746,345 shares in the company, valued at approximately $18,681,015.35. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CRO Joseph S. Manni sold 1,361 shares of CeriBell stock in a transaction on Friday, August 21st. The stock was sold at an average price of $24.02, for a total value of $32,691.22. Following the transaction, the executive owned 55,956 shares in the company, valued at approximately $1,344,063.12. This represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 174,905 shares of company stock valued at $4,312,995 in the last quarter. 17.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on CBLL shares. Weiss Ratings upgraded shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 16th. Barclays raised CeriBell to a “neutral” rating in a report on Tuesday, August 18th. TD Cowen raised their price target on CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a report on Friday, October 2nd. Raymond James Financial restated a “strong-buy” rating and issued a $29.00 price target on shares of CeriBell in a research report on Thursday, September 3rd. Finally, BTIG Research reaffirmed a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research report on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $27.00.

About CeriBell

CeriBell, Inc is a medical technology company that develops artificial intelligence-enabled neurological diagnostic products. Its technology is designed to help healthcare professionals rapidly identify and monitor seizures, including nonconvulsive seizures that may be difficult to recognize through a standard clinical examination.

The company’s primary product is the Ceribell Rapid Response EEG system, a portable electroencephalography platform that combines a wireless EEG recorder, a simplified disposable headband, and software-based analysis tools.